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Type 1 diabetes results from the autoimmune destruction of the insulin-producing pancreatic beta (β) cells. Patients with type 1
diabetes control their blood glucose levels using several daily injections of exogenous insulin; however, this does not eliminate the
long-term complications of hyperglycaemia. Currently, the only clinically viable treatments for type 1 diabetes are whole pancreas
and islet transplantation. As a result, there is an urgent need to develop alternative therapies. Recently, cell and gene therapy have
shown promise as a potential cure for type 1 diabetes through the genetic engineering of ‘artiﬁcial’ β cells to regulate blood
glucose levels without adverse side effects and the need for immunosuppression. This review compares putative target cells and
the use of pancreatic transcription factors for gene modiﬁcation, with the ultimate goal of engineering a glucose-responsive
‘artiﬁcial’ β cell that mimics the function of pancreatic β cells, while avoiding autoimmune destruction.
Gene Therapy (2015) 22, 1–8; doi:10.1038/gt.2014.93; published online 23 October 2014
INTRODUCTION
Type 1 diabetes (T1D) results from the autoimmune destruction of
the insulin-producing pancreatic beta (β) cells, resulting in
hyperglycaemia.1 Currently, patients with T1D control their blood
glucose levels using several daily injections of exogenous insulin;2
however, this does not mimic the exquisite metabolic respon-
siveness of the β cell. Insulin therapy delays, but does not
eliminate hyperglycaemic episodes and chronic complications
associated with extended periods of hyperglycaemia.3,4 Of equal,
if not more, concern to the patient are the life-threatening
hypoglycaemic episodes that are exacerbated because of
hypoglycaemia unawareness, a phenomenon that worsens with
both disease duration and maintenance of blood glucose levels
close to normal values.4
Currently, whole pancreas or islet transplantation are the only
clinically viable treatments for T1D. However, they are limited by a
shortage of pancreas donors and the requirement for lifelong
immunosuppression, which carries adverse side effects and can
compromise the survival of transplanted tissue.5 Developing cell
and gene therapy strategies show immense promise as alternate
therapies, potentially avoiding both the requirement for immuno-
suppression and recurrent autoimmunity.
Over the past decade, there have been several attempts to
generate ‘artiﬁcial’ β cells that produce insulin in response to
glucose in a regulated manner. Several approaches have been
explored including: (i) the dedifferentiation and directed transdif-
ferentiation of autologous cells6–9 ex vivo followed by transplanta-
tion, (ii) in vivo transdifferentiation via the direct delivery of viral
vectors to target organs; and (iii) the genetic modiﬁcation and
expansion of various stem cells ex vivo that can then be
transplanted. The production of a functional ‘artiﬁcial’ β cell, via
genetic manipulation, requires a comprehensive understanding of
the pancreatic developmental process. The temporal expression of
the various pancreatic transcription factors, their role in determin-
ing endocrine cell fate and their involvement in mature β-cell
function are key factors for consideration in the design of an
artiﬁcial β cell. The types of vectors used for gene delivery and the
selection of an ideal candidate cell type for differentiation towards
a β-cell phenotype are key considerations for achieving this
objective. The cell type of choice for the gene therapy of diabetes
is not the β cell. β Cells are reduced or absent in patients with T1D,
because of autoimmune destruction. This fact will actively work
against gene therapists trying to derive surrogate β cells from
some stem cells and islet regeneration studies. The ultimate goal
for the gene therapy of T1D is to produce a cell that has the ability
to process, store and secrete insulin and maintain normal glucose
tolerance in response to ﬂuctuating blood glucose concentrations,
while avoiding autoimmune attack. This review will compare
putative non-pancreatic target cells, viral vectors and pancreatic
transcription factors for gene modiﬁcation to achieve this goal.
SELECTING AN IDEAL TARGET CELL
The ﬁrst trials of insulin gene therapy were performed using
somatic cells, such as monkey kidney cells and ﬁbroblasts.10,11
However, these cells were unable to produce biologically active
insulin, as they did not express proinsulin-processing enzymes. As
a result, attention turned to autologous cells that are derived from
an endodermal origin and possess characteristics similar to those
of β cells12 (Table 1). The ideal surrogate for β-cell engineering
would be able to sense minute changes in glucose, process
proinsulin to insulin and c-peptide and store this mature insulin
for later secretion.
Endocrine cells have been examined, in particular, pituitary
cells that contain both proinsulin-processing enzymes and
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secretory granules. A murine pituitary cell line (AtT20MtIns-1.4)
transfected in vitro with a recombinant plasmid containing human
preproinsulin cDNA produced biologically active insulin; however,
glucose responsiveness was absent in these cells.13 After
transfection with both glucose transporter 2 and glucokinase,
the AtT20Ins cells became glucose responsive, at subphysiologic
levels. Also, the in vivo secretion of adenocorticotropic hormone
stimulated glucocorticoid synthesis, inhibiting insulin function and
therefore limiting their therapeutic efﬁcacy.14
Muscle cells have been only sparingly studied because of their
lack of insulin proconvertases and storage vesicles. As a result,
they require intensive genetic manipulation to produce functional
β cells, which is not optimal for therapeutic applications. None-
theless, muscle-targeted gene therapy for the treatment of T1D
has been explored. Implantation of vascular smooth muscle cells
transduced with furin-cleavable insulin under the control of a
glucose-regulatable promoter into spontaneously diabetic con-
genic BioBreeding rats has been attempted. This resulted in the
reduction of blood glucose levels in two of the eight rats for a
period of 6 weeks; however, insulin therapy was still required.15
Regulated insulin secretion resulted in markedly lower exogenous
insulin requirements to sustain normal growth without any
hypoglycaemic episodes. Another study indicated that it was
possible to reverse diabetes in streptozotocin (STZ) mice for
44 months following the dual expression of insulin and
glucokinase in muscle.16 A synergenic action in the skeletal
muscle between the insulin produced and the increased
phosphorylation of glucokinase was established, preventing
hyperglycaemia.
Liver cells are derived from the same endodermal origin as the
pancreas and consequently are more amenable to pancreatic
transdifferentiation when compared with other cell types.17
Similar to pancreatic β cells, they express the key glucose-
responsive elements glucose transporter 2 and glucokinase,
making hepatocytes an attractive target cell for engineering
artiﬁcial β cells. Although hepatocytes do not contain proinsulin-
processing enzymes and lack secretory granules, this function may
be induced via expression of insulin analogues cleaved by furin in
the liver.7,8 However, truly regulated secretion to a glucose
stimulus requires the presence of insulin storage granules. Within
seconds of being exposed to glucose, the cell transports glucose
across the membrane and metabolizes it. The secretory granule
migrates to the surface of the cell, fuses with the membrane and
secretes its contents, thus regulating blood glucose levels. The
result in many studies that have simply expressed either insulin or
insulin analogues in liver cell lines or animal livers18–20 has been
the synthesis and constitutive release of insulin, but not its storage
or regulated secretion. By comparison, our laboratory has shown
that the expression of insulin in a liver cell line that had
endogenous expression of β-cell transcription factors led to
pancreatic transdifferentiation, formation of secretory granules
and a regulated response to glucose with reversal of diabetes.7
Owing to the extensive immunomodulatory capacity of
mesenchymal stem cells (MSCs),21–24 their therapeutic potential
as a treatment for T1D in an autologous or allogeneic setting has
been pursued, with some of these studies currently under human
clinical trials.25 Although the use of native MSC transplantation in
animal models of diabetes has been undertaken,26,27 the majority
of clinical MSC research has focused on the in vitro production of
insulin-producing cells (IPCs), via the application of differentiation
protocols to upregulate the expression of β-cell transcription
factors.28
Native bone marrow-derived mesenchymal stem cells (BMSCs)
do express some β-cell transcription factors, and therefore have a
potential predisposition for differentiation towards a β-cell
phenotype. IPCs can be obtained from BMSCs via the use of a
high glucose culture medium29 or nicotinamide-enriched medium
to induce differentiation.30 The resulting differentiated cells
express insulin, at both the mRNA and protein level, and
ameliorate hyperglycaemia in STZ diabetic rats.30 Similarly, it is
possible to induce IPC differentiation from BMSCs in vitro using a
three-step protocol, which results in high expression levels of
Pdx-1, insulin and glucagon, and glucose-responsive production of
insulin.31 More recently, the combination of a gene and cell
therapy successfully produced IPCs from BMSCs. Retroviral
transduction of BMSCs with Pdx-1 resulted in the production of
insulin in response to increasing glucose concentrations, and
when these cells were transplanted under the renal capsule of STZ
diabetic severe-combined immunodeﬁcient mice, the mice
showed reduced blood glucose concentrations beginning 12 days
posttransplantation, and normal glucose tolerance until 6–8 weeks
posttransplantation.32
VECTOR CHOICE FOR GENE THERAPY
By exploiting the natural ability of viruses to infect and deliver
genes into cells, engineered viral vectors that do not replicate and
efﬁciently transduce genes into infected target cells have been
developed. Their suitability for gene transfer into target cells is
determined by whether they are integrating or non-integrating,
the target cell type and the nature of gene expression required
(Table 2). Ideally, β-cell engineering would use integrating viral
vectors to provide sustained gene transfer in daughter cells over
the life of the patient resulting in a sustained therapeutic beneﬁt.
Retroviral
Retroviral vectors are the most widely used gene delivery vector,
and are derived from disabled murine viruses.33 The advantage of
integration into the host’s genome is however overshadowed by
the risk of insertional mutagenesis.34 This was ﬁrst recognized in
1999 following the treatment of nine severe-combined immuno-
deﬁciency patients with a retroviral vector, which resulted in the
development of leukaemia in four of the nine patients.35 This
study showed that retroviruses in general have site-speciﬁc
integration preferences in close proximity to the transcriptional
regulatory sequences of proto-oncogenes.36 Retroviral gene
transfer is also limited by their ability to only transduce dividing
cells, and can therefore only be targeted towards selected cell or
tissue types. This ultimately becomes a challenge when the target
tissue is composed predominantly of non-dividing cells, such as
the liver. Xu et al.37 studied the retroviral transduction of BMSCs
with an insulin gene under the control of the cytomegalovirus
promoter, and the ability of these transduced cells to restore
normoglycaemia in STZ diabetic mice. It was found that the
BMSCs successfully expressed insulin and were able to maintain
Table 1. Summary of target cells and the degree of β-cell similarity
Characteristics Target cell
Liver Pituitary Muscle K
cells
BMSC
Endodermal origin + − − − +
Possession of β-cell transcription
factors
− − − − +
Glucose-sensing system + − − + −
Processing enzymes − + − + −
Glucose-regulatable promoter + − − + −
Exocytosis system − + − + −
Autologous use + + + + +
Allogeneic use − − − − +
Abbreviation: BMSC, bone marrow-derived mesenchymal stem cell.
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normoglycaemia for at least 42 days. In addition, the transduced
BMSCs were able to evade autoimmune destruction that ordinarily
targets pancreatic islets.
Adenoviral
Adenoviral vectors were initially studied owing to their ability to
transduce non-dividing cells with high efﬁciency. However, these
vectors transfer their genes episomally and subsequently provide
only transient gene expression.33,38 In addition, immune responses
against the viral proteins and in some cases the transgene itself
have been reported.39,40 To overcome the immunogenicity of the
viral capsid proteins, a ‘gutless’ adenovirus was developed, in
which the majority of the viral genes were removed.41 Although
reduced immunogenicity was observed with the new-generation
adenoviral vectors, immunosuppressants are still required to
manage immune responses activated following treatment.42 The
prevalence of pre-existing immunity to adenovirus in humans
would also limit the multiple administrations of vector required to
maintain long-term therapeutic effects. These characteristics
actively work against choosing adenoviral vectors to produce an
artiﬁcial β cell.
Adeno-associated
Adeno-associated viral vectors are replication-defective parvo-
viruses able to transduce both dividing and non-dividing cells.
Although they show a limited gene cargo capacity (o5 kb), they
preferentially integrate into the host genome at a speciﬁc site on
chromosome 19.43 This renders adeno-associated viral vectors a
safe and attractive gene delivery candidate as their insertion sites
can be predicted and potentially oncogenic consequences
avoided. Adeno-associated viral vectors have been used in the
treatment of T1D, speciﬁcally to deliver directly the preproinsulin
gene to livers of chemically STZ mice,44 where proinsulin was
produced in the liver and blood glucose levels were transiently
reduced. This study supports the utility of adeno-associated viral
vectors for insulin gene transfer to non-dividing hepatocytes.
Lentiviral
Lentiviral vectors are retroviruses with the ability to transduce
non-dividing cells as well as dividing cells, which makes them
attractive candidates for the transduction of a variety of cell
lineages.45 Lentiviral vectors are derived from human immunode-
ﬁciency virus, and, accordingly, biosafety was initially a concern
surrounding their suitability as human therapeutics. Construction
of self-inactivating human immunodeﬁciency virus-derived vec-
tors, with deletions in the long terminal repeat promoter,
decreases the likelihood of generating a replication-competent
virus,46 and subsequently provides greater safety for clinical
application. As a result, lentiviral vectors have shown promise for
corrective gene therapy and are currently the gene transfer vector
of choice within our laboratory. We have successfully used a
lentiviral vector (HMD) to deliver furin-cleavable insulin to the
livers of STZ diabetic rats,8 non-obese diabetic mice47 and
pancreatectomized Westran pigs.48 In these animal models, we
have seen spontaneous expression of an array of β-cell transcrip-
tion factors, formation of granules and regulated and permanent
correction of diabetes.8,47,48 Liver to pancreas transdifferentiation
is relatively common in other situations,49 especially when the
liver is insulted. The pancreatic transdifferentiation in our studies
was undoubtedly related to the combination of the surgical
procedure used, which isolates the liver from the circulation, the
lentiviral vector and the microenvironment of diabetic hypergly-
caemia, which collectively insulted the liver cells. By comparison,
the simple injection of insulin into the portal circulation led to
unregulated constitutive insulin release, no pancreatic transdiffer-
entiation and an abnormal glucose response47 as seen in a similar
study by Elsner et al.19 Although lentiviral expression of insulin has
become a popular choice for gene therapy in some rodent models
showing amelioration of hyperglycaemia, normal glucose toler-
ance was not achieved because of an absence of β-cell
transcription factor expression and resultant pancreatic
transdifferentiation.50,51
β-CELL TRANSCRIPTION FACTORS
The pancreas as a whole organ is derived from the endoderm
during embryonic development. Transcription factors have a
signiﬁcant role in pancreatic embryogenesis, particularly in
determining islet cell differentiation (Figure 1). During adult life,
transcription factors regulate the expression of islet cell
hormones.52
Forkhead box factor FoxA1 and FoxA2 expression is directly
implicated in endodermal formation, with FoxA2 deletions
resulting in the disruption of endoderm formation in mouse
models.53 Homeobox factor Pdx-1 is considered the ‘master
regulator’ as it has a signiﬁcant role in the early development of
the pancreas, being expressed in both the endoderm and
pancreatic buds.52,54 Pdx-1 expression levels are regulated by
the interaction between the transcription factors, hepatocyte
nuclear factor-3β, hepatocyte nuclear factor-1α and SP1/3, and
Pdx-1 itself.55 Homozygous Pdx-1− /− mice are apancreatic, and
while they survive foetal development, they die a few days
following birth.56,57 This conﬁrms the necessity of embryonic Pdx-1
expression for successful pancreatic development.




Retroviral 8–10 Integrates into host genome
No expression of viral proteins
Long-term expression
Only transduces dividing cells
Limited insertion capacity
Random integration into host genome
Adenoviral o8 Transduces dividing and non-dividing cells
Produces high titres of virus
High levels of expression
Immune response to viral proteins
No integration into host genome
Short-term expression
Adeno-associated o5 Transduces dividing and non-dividing cells




Can generate neutralizing antibodies
Limited insertion size
Lentiviral o10 Transduces dividing and non-dividing cells
Stable, long-term expression
Can be generated into a self-inactivating vector
Possible toxicity because of viral proteins in packaging construct
Random integration into host genome
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Following the fusion of the dorsal and ventral buds, the
differentiation of exocrine and endocrine pancreatic compart-
ments occurs rapidly, with the basic helix–loop–helix factors, Hes-1
and Neurog3, in the pancreatic precursor directing the respective
compartmental fates via notch signalling.58 The notch signalling
pathway has a major role in the control of cell identity,
proliferation, differentiation and apoptosis.59 Subsequent differ-
entiation of the various islet cellvtypes (α, β, γ and pancreatic
polypeptide) is directed by the hierarchical expression of various
transcription factors.52 Lineage analyses have shown that all
hormone-producing cells express Neurog3.58 In mice, Neurog3
deletions result in the absence of endocrine cells,60 testament to
its necessity in endocrine cell development. Neurog3 activates the
persistent expression of NeuroD1 that maintains the endocrine cell
differentiation programme.61 In fact, NeuroD1− /− mice show a
reduction in the development of insulin-producing β cells.62
As soon as the endocrine cell fate has been programmed, the
paired homeobox factors, Pax4 and Pax6, direct the fates of
individual hormone-producing cells.52 Studies in mice show that
homozygous Pax4 deﬁciency results in a lack of β and γ cells,52,54
and mice that are homozygous Pax6 deﬁcient lack α cells.63
Collectively, these studies suggest that Pax4 is required for
determining β- and γ-cell fate, whereas Pax6 is required for
determining α-cell fate.
Differentiation into β cells is ultimately driven by the NK
homeobox factors, Nkx2.2 and Nkx6.1. Knocking out the Nkx6.1
gene in mice results in the absence of β cells;64 however, all other
cell types develop. Interestingly, Nkx2.2 is expressed in other cell
types including α and pancreatic polypeptide cells; however when
Nkx2.2 is knocked out, insulin-producing cells are absent.65
Consequently, Nkx2.2 and Nkx6.1 are imperative in β-cell
differentiation. More recently, a leucine zipper transcription factor
(MafA) has been discovered downstream of Nkx6.1 in the lineage
analysis and was found to be involved in the maintenance of
β-cell function, speciﬁcally through interactions with Pdx-1 and
NeuroD1 that modulated insulin transcription.66 The modiﬁcation
of transcription and subcellular localization of fundamental
transcription factors, such as FoxA2, MafA, NeuroD1 and Pdx-1,
will alter important cellular processes such as β-cell differentiation,
cell cycle arrest and function, and accordingly represents
an interesting potential target for the development of an artiﬁcial
β cell.67
DIRECT TRANSFER OF PANCREATIC TRANSCRIPTION FACTORS
Genetically engineering other cells within the body to produce
insulin is an attractive alternative to pancreas and islet transplan-
tation as these cells would not likely express the same
autoantigens that caused β-cell destruction in the ﬁrst instance.
Owing to the common origin of the liver and pancreas,12 the
ability to transdifferentiate tissues from the liver to the pancreas
has been studied to a greater extent than other tissues types,
particularly for the generation of IPCs through the transfer of
pancreatic transcription factors.
Pdx-1
Ferber et al.9 demonstrated the potential of transcription factors to
be directly delivered to liver tissue, via a recombinant adenovirus-
mediated transfer of Pdx-1. Considering Pdx-1 has a signiﬁcant role
in early embryonic development of the pancreas, an attempt to
demonstrate the ability of adenovirus-mediated delivery of Pdx-1
to ameliorate hyperglycaemia by inducing expression of endo-
genous insulin was performed. Results showed that expression of
Pdx-1 in livers of diabetic mice induced insulin expression and
secretion leading to restoration of normoglycaemia. However,
Figure 1. Schematic representation of the transcription factor hierarchy involved in pancreatic development and cellular differentiation. The
early endoderm of the gut receives signals from the mesenchyme and notochord to initiate formation of the pancreatic buds, with expression
of FoxA2 and Hb9 detectable in the pancreatic precursors. Pdx-1 then drives the subsequent differentiation of the pancreatic precursor cells by
interacting with Pbx-1. Neurog3 and Hes-1 mediate endocrine and exocrine differentiation, respectively, with NeuroD1 functioning to maintain
the endocrine cell fate. Pax6 and Pax4 then mediate the differentiation of α and β cells, respectively, with the ﬁnal differentiation process
towards a β-cell phenotype being governed by Nkx2.2 and Nkx6.1.
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normoglycaemia was transient and only maintained for 8 days. In
addition, exocrine differentiation of liver to pancreatic tissue
resulted in the development of hepatitis and an increased
likelihood of autoimmune destruction.9,68
Similarly, Kojima et al.68 used a helper-dependent adenovirus to
deliver Pdx-1 to the livers of STZ diabetic mice. These mice
developed hepatitis because of unexpected exocrine differentia-
tion of the transduced cells. This was likely related to the use of a
potent ubiquitously expressed elongation factor-1α promoter,
which resulted in continuous unrestricted expression of Pdx-1 at
high levels. To date, several studies in which Pdx-1 has been
transferred to hepatocytes to induce the process of transdiffer-
entiation have been performed.69–73 In addition, direct delivery of
Pdx-1 has been achieved in a variety of other differentiated cell
types, including mouse pancreas via the bile duct,74 rat intestinal
epithelium-derived cells (IEC-6)75 and primary duct cells.76 One
study showed how combinations of pancreatic transcription
factors (Pdx-1, Neurog3 and MafA) were successful in converting
pancreatic exocrine cells in vivo to closely resemble β cells,77 and
thus provided evidence for the use of transcription factor
combinations. The newly generated IPCs are indistinguishable
from normal islets and display all the characteristic hallmarks of
normal β cells; however, the limited number of successfully
converted exocrine cells and the fact they did not organize
themselves into islet structures limited their effectiveness.
Pdx-1 continues to be used as a mediator of IPC production
because of its proven ability to induce pancreatic transdifferentia-
tion. The move to stem cells as targets has come as no surprise
considering their plasticity and regenerative capabilities. Pdx-1 has
been delivered to MSCs from a variety of sources, including
BMSC,32,78–82 umbilical cord MSC83 and adipose-derived MSC84–86
with varying success in the generation of glucose-responsive IPCs.
Despite the obvious attraction of MSCs as targets for Pdx-1
delivery, embryonic stem cells (ESCs) have also been pursued as a
potential target. A study by Miyazaki et al.87 showed that a murine
ESC line (EB3) could be induced to differentiate into IPCs following
transfection with Pdx-1; however, transdifferentiation was not
substantial enough for therapeutic use owing to a lack of
expression of the insulin 1, glucagon, pancreatic polypeptide
gene or glucose transporter 2 genes, which are all speciﬁc to the
endocrine pancreas in vivo. This was followed by a number of
studies in other ESC lines88–90 showing their capacity to
differentiate into IPCs.
Neurog3
The role of Neurog3 in deﬁning endocrine cell fate would logically
point towards its more frequent use in gene therapy; however this
is not the case. Most studies have reported low levels of insulin
production after delivery of Neurog3.71,76,91–93 Of the few reported
attempts at using Neurog3 for β-cell engineering, a study using
adenoviral transfer of Neurog3 and betacellulin to hepatic
progenitor cells (oval cells) resulted in the production of insulin
and transdifferentiation of the oval cell population.94 However, as
mentioned previously, the most successful use of Neurog3 delivery
was observed using a combinatorial approach.77
NeuroD1
To prevent Pdx-1-induced exocrine differentiation, Kojima et al.68
expressed NeuroD1 in conjunction with betacellulin within a
helper-dependent adenovirus vector to the livers of STZ-treated
diabetic mice. It was found that NeuroD1-betacellulin delivery
restored and maintained normoglycaemia for 4120 days, with
associated upregulation of the upstream and downstream
pancreatic transcription factors, including Neurog3, Pax6, Pax4,
Nkx2.2 and Nkx6.1. However, while the use of betacellulin would
not likely be acceptable for clinical application, the use of NeuroD1
resulted in no signiﬁcant hepatotoxicity or development of
hepatitis, marking NeuroD1 as a worthy alternative transcription
factor for directing differentiation to a β-cell-like phenotype.
NeuroD1 is also an ideal alternative as it has been shown to be the
strongest inducer of insulin expression (as compared with Pdx-1,
Neurog3 and Pax4) in primary duct cells.76 Similar studies showing
the ability of NeuroD1 to induce insulin expression have been
performed using hepatocytes.95
Promising results using viral delivery of NeuroD1 to hepatocytes
have also been reported by our laboratory. Speciﬁcally, a
genetically modiﬁed rat liver cell line (H4IIE), which does not
express β-cell transcription factors, was engineered to express
both insulin and NeuroD1.96 The engineered cell line developed
storage granules and reversed diabetes in non-obese diabetic/
severe-combined immunodeﬁcient mice following transplanta-
tion. It also stimulated the expression of the β-cell transcription
factors, Pdx-1, NeuroD1, Pax6, Nkx2.2 and Nkx6.1, in addition to rat
insulin 1 and 2, glucagon, somatostatin, proconvertase 1 and 2
and pancreatic polypeptide. The engineered cells also regulated
secretion of insulin in response to increasing concentrations of
glucose. As a result, NeuroD1 could potentially be used in future
gene therapy protocols to induce safe differentiation of target
tissues.
Pax4
As mentioned earlier, Pax4 deﬁciencies in mice results in the lack
of β and γ cells;52,54 therefore, it can be deduced that Pax4 is
required for determining β-cell fate and could be used for the
generation of IPCs. Overexpression of Pax4 in mouse embryonic
stem cells selected for nestin expression has been shown to drive
differentiation to a β-cell phenotype,97 with the resultant IPCs
capable of maintaining normal blood glucose levels for 14 days.
Similarly, Liew et al.98 reported that overexpression of Pax4 in
human ESCs enhances their propensity to form putative β cells.
However, the capacity for teratoma formation of undifferentiated
ESCs limits their potential for clinical application.
Nkx6.1
The β-cell-speciﬁc expression of Nkx6.1 theoretically makes it an
ideal choice as a factor to drive β-cell differentiation. However, a
study by Gefen-Halevi et al.99 showed that ectopic expression of
Nkx6.1 alone, although capable of inducing the expression of
immature pancreatic markers, such as Neurog3 and Isl-1, was not
capable of inducing expression of pancreatic hormones. In
addition, Nkx6.1 did not appear to be a strong inducer of
expression of upper-hierarchy β-cell transcription factors such as
Pdx-1 and NeuroD1. In fact, only upon coexpression with ectopic
Pdx-1 was there substantial insulin expression and glucose-
regulated processed hormone secretion. Consequently, the
inability to induce expression of the full repertoire of β-cell
transcription factors makes Nkx6.1 an inferior choice for β-cell
engineering.
CONCLUSIONS AND FUTURE DIRECTIONS
With respect to β-cell replacement strategies, direct delivery of
β-cell transcription factors presents an alternative method of
achieving a β-cell-like phenotype in autologous tissues. The
generation of sufﬁcient quantities of IPCs on a large scale and
isolation of pure IPCs is of utmost importance for the success of
any bench-to-clinic therapy of T1D. Although work on direct
delivery of transcription factors has focused predominantly on
hepatocytes as a target in the past decade, the emergence of stem
cells and their suitability as a target should be further investigated
in the future. Limiting the use of an autologous cell therapy is the
considerable effort required to generate a single therapy for
individuals. Furthermore, the potential development of a full
repertoire of β-cell autoantigens could increase susceptibility of
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the grafts to recurrent autoimmunity. It is also clear that the choice
of transcription factor for direct delivery has a signiﬁcant role in
determining the success of the cell and gene therapy, as exocrine
differentiation and true conversion to a pancreatic phenotype are
potential deleterious outcomes. Ideally, an allogeneic cell therapy
that is capable of circumventing the autoimmune response would
overcome these limitations.
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